Fig. 3.

Kaplan–Meier survival estimation of stage III melanoma patients by CCR5 status. Curves showing the overall survival of cutaneous melanoma patients starting with the time of first diagnosis of stage III disease. Survival probabilities were compared by the CCR5Δ32 polymorphism status using the log rank test. a All 302 patients; wt/wt, 259 patients; wt/Δ32 or Δ32/Δ32, 43 patients; P = 0.99; b 107 patients treated with at least one immunotherapy regimen during stage III disease; wt/wt, 96 patients; wt/Δ32 or Δ32/Δ32, 11 patients; P = 0.61; c 195 patients without immunotherapy during stage III disease; wt/wt, 163 patients; wt/Δ32 or Δ32/Δ32, 32 patients; P = 0.66. Vertical bars indicate censored observations. The number of patients at risk is given underneath each graph